InvestorBrandNetwork (IBN) Content Platform

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has begun preparations for good manufacturing practices (“GMP”) production of a capsule formulation of CYB003, its proprietary deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder (“MDD”). According to the announcement, the formation is stable, dose and patient friendly, and is commercially scalable. The company noted that it anticipates shipping the CYB003 capsules to clinical sites by first quarter 2024. “The development of a capsule formulation of CYB003 represents a meaningful advancement toward a commercially viable and more convenient dosing option that is potentially suitable for a future phase 3 trial,” said Cybin CEO Doug Drysdale in the press release. “We are very pleased with the progression of our CYB003 program in MDD thus far. Preparations for GMP manufacturing of CYB003 capsules continue to build on our efforts to progress an improved treatment option for people with major depressive disorder. Coupled with our partnership with Worldwide Clinical Trials, a global CRO with deep expertise in psychedelic clinical trials, and the development of EMBARK(CT), a scalable model of our psychedelic facilitation program, these efforts are a testament to our clinical execution and capabilities at each step along our development pathway.”

To view the full press release, visit https://ibn.fm/rFsom

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today provided an interim analysis from its ongoing phase 1B trial of Next Generation Capecitabine (“NGC-Cap”) in patients with gastrointestinal cancer, which identifies a personalized treatment approach that may yield improved safety and treatment efficacy. “The presence of DPD as expressed by the plasma concentration of FBAL provides us important information that may confirm our hypothesis that we can optimize our dosing of NGC-Cap to maintain efficacy and minimize side effects by carefully tracking each individual patient following an initial dosing of our novel chemotherapy,” said Sian Bigora, Pharm.D., Processa’s chief development and regulatory officer. “By following the chemical concentration in the plasma in each patient, we may be able to actually optimize therapy through individualization of each patient’s dosing regimen. We find these results, albeit early results, to be very encouraging.”

To view the full press release, visit https://ibn.fm/LFk1N

About Processa Pharmaceuticals Inc.

Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy drugs. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its approach to drug development is based on more than 30 years of drug development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, Processa has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s Next Generation Chemotherapy drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each Next Generation Chemotherapy drug. Currently in its pipeline are three Next Generation Chemotherapy drugs: Next Generation Capecitabine (“PCS6422” and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (“PCS3117” to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (“PCS11T” to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

GolfLync, the premier social media platform for golf enthusiasts, is proud to announce a significant milestone, surpassing 50,000 members across the United States. The exponential growth is a testament to the platform’s ability to bring golfers together, fostering vibrant golfing communities and connections that continue to flourish.

From local golf clubs to nationwide networks, GolfLync’s Virtual Golf Clubs(TM) (“VGC”) have transformed the way golfers connect, share, and experience the game they love. Members are embracing the platform’s innovative features, with private and public VGCs serving as hubs for planning…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

EverGen (TSX.V: EVGN) (OTCQX: EVGIF) today announced plans to release its 2023 second quarter financial results after market close on Aug. 23, 2023. At 10:00 a.m. ET on the following day, Aug. 24, EverGen will hold a results and corporate update conference call, hosted by Chief Executive Officer Chase Edgelow. Interested parties should visit https://ibn.fm/6TXZK to register for the event and access the webcast.

To view the full press release, visit https://ibn.fm/pcIwO

About EverGen Infrastructure Corp.

EverGen, Canada’s renewable natural gas (“RNG”) infrastructure platform, is combating climate change and helping communities contribute to a sustainable future. Headquartered on the West Coast of Canada, EverGen is an established independent renewable energy producer, which acquires, develops, builds, owns and operates a portfolio of renewable natural gas, waste to energy and related infrastructure projects. EverGen is focused on Canada, with continued growth expected across other regions in North America and beyond. For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Blue Hat Interactive (NASDAQ: BHAT) has completed the issue of $29.8 million of ordinary shares. According to the announcement, the company anticipates continued development of the commodities trading business, especially in trading gold and jewelry, which will create sustainable values for global shareholders. “The completion of this issuance marks a significant development for BHAT, continuing the company’s transformation to commodity trading since the third quarter of 2022,” said BHAT CEO Xiaodong Chen in the press release. “The company has appointed Mr. Pan Weicheng as the CSO in May 2023. Under the leadership of Mr. Pan, a new business system was established — commodity trading with artificial intelligence analysis. At the same time, BHAT has also divested its Variable Interest Entity (‘VIE’) structure within mainland China. These adjustments are strategic and enduring. BHAT will gradually shift towards international growth. In the future, BHAT plans to expand and shift its business’s focus to Southeast Asia and the United States. The presence and development of artificial intelligence is inevitable. Thus, utilizing AI technology to influence the existing commodity trading framework is at the core of our new strategy. We are enthusiastic about this forward-thinking endeavor. We envision a working model that is fully implemented and results in positive outcomes, which we have already begun to achieve in the past three quarters.”

To view the full press release, visit https://ibn.fm/n6MkF

About Blue Hat Interactive Entertainment Technology

Blue Hat is developing a commodity trading with artificial intelligence analysis focus.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Financial analysts, business owners, investors, financial institutions, and regulators, are invited to attend FinovateFall, held in the Marriott Marquis Times Square, New York City, September 11-13, 2023. The much-awaited event is returning to bustling New York City. Featuring interactive sessions, live demos, and unlimited entertainment options, FinovateFall promises to be a fintech extravaganza that sparks innovation and creativity.

Important thought leaders will share their perspectives on the future of finance through engaging seminars and live demos showing the latest in fintech developments, all while offering off-hours NYC entertainment opportunities that will keep participants captivated. New York’s unmatched…

Read More>>

To learn more, please visit https://ibn.fm/sLe8Y.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, is reporting its financial and operating results for the second quarter and six-month period ended June 30, 2023. Highlights of the report include a 31% decrease in operating expenses quarter over quarter and 25% year to date, a reflection of the company’s cost-cutting initiatives; revenue of $3.4 million for the Q2 2023 and $7.3 million for the six-month period, compared to $4.2 million and $7.8 million for the three and six months ended June 30, 2022, respectively; and gross profit of $2.1 million for the quarter and $4.4 million for the six-month period, compared to $2.6 million and $5.1 million for the comparable periods in 2022, respectively. The company reported cash and cash equivalents totaled $3.9 million on June 30, 2023. Operational highlights include an estimated 40,000 patients being treated with the Vivos Method and more than 1,800 dentists trained in the use of the Vivos Method and related value-added services as well as the announcement of the results of a clinical observational study on the application of the POD(R) (now being rebranded as the Vida) in the treatment and prevention of migraine headaches.

“Throughout this year, we significantly reduced our cash burn, which led to a 31% second quarter over quarter, and 25% year over year reduction in operating expenses,” said Vivos chair and CEO Kirk Huntsman in the press release. “At the same time, we expanded our product offerings to address a broader spectrum of patient needs and price points to drive revenue growth. This included our acquisition of certain key patents, trademarks, product rights and trade secrets earlier in 2023, which filled a gap in our product offerings to providers and patients. We continue to believe that these developments will allow us to begin to see revenue improvement here in the second half of 2023. . . . Through the combination of our strategic revenue initiatives, internal operating cost reductions and new capital raising initiatives, we believe we have positioned Vivos to achieve revenue growth and, ultimately, cash-flow positive operations and profitability in the foreseeable future. In summary, while the larger economic and market environment is creating challenges for both the medical and dental communities, Vivos has taken steps to address those challenges, and our long-term growth drivers remain in place.

To view the full press release, visit https://ibn.fm/7DdAx

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

VPR Brands (OTC: VPRB), a licensing company owning patents and trademarks as well as a market leader for the design and sale of electronic cigarettes, or vaporizers, for nicotine, cannabis and cannabidiol (“CBD”) and other related accessories such as lighters, is reporting its second-quarter 2023 financial results. Highlights of the report show increased revenues and record profits when compared to previous quarters. The company noted that while it was able to increase Q2 2023 revenues over 2022 by an estimated $1 million to $1,909,529, and year-to-date six-month revenue by more than $2 million to $4,990,550, it was able to reduce operating expenses for the two time periods as well. The report showed that net income for VPR Brands increased to more than $928,322 in Q2 2023, up from $73,733 in Q2 2022 and $953,636 year to date, compared to a net loss of $73,508 for the six-month period ending June 30, 2022. “We have been able to successfully license and monetize our ELF brand trademark this year while aggressively protecting the mark in the courts and creating a monumental asset for the company and we are now focusing on developing business for our other trademarks as well,” said VPR Brands CEO Kevin Frija in the press release. “We believe partnering as a Licensor with experienced and well capitalized licensees to expand our brand portfolios business is the model that will work best for the company in the long run.”

To view the full press release, visit https://ibn.fm/wSX25

About VPR Brands LP

VPR Brands is a technology company, as well as an IP holding company. The company is engaged in various monetization strategies of a U.S. patent that the company owns covering electronic cigarette, electronic cigar and personal vaporizer patents, as well as a patent for an inverted pocket lighter. The company also has several trademarks (ELF, PHANTOM, HRB, VPOD, VAPOR X, and RIPPER) for which it is also engaged in licensing and various monetization strategies. VPR Brands also designs, develops, markets and distributes products, including the HoneyStick brand of vaporizers and the Goldline CBD products, oriented toward the cannabis markets. This allows the company to capitalize on the rapidly growing expansion within the cannabis markets. The company is also identifying electronic cigarette companies that may be infringing its patents and trademarks and exploring options to license and/or enforce those patents. The company is now also selling DISSIM brand pocket lighters for which it holds a U.S. patent and patents pending. The company also has patents pending in the cigar accessory space and sells these proprietary accessories. For more information about the company, visit www.VPRBrands.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has announced the date for the conference call to discuss financial results for the second quarter ended June 30, 2023. The call had initially been scheduled for Aug. 14, 2023, but has been rescheduled for today at 6 p.m. ET. According to the announcement, company officials will host the call to review the company’s financial results and provide an overview of the company’s recent milestones and developments. Those interested in accessing the call can dial 877-451-6152 (toll free) or 201-389-0879 (international callers). A replay of the call, which will be available until Aug. 30, 2023, will be available shortly after the call concludes. The replay can be accessed by dialing 844-512-2921 (toll free) or 412-317-6671 (international callers). The passcode for both the live and replay calls is 13740723. A live webcast of the call is also available.

“As previously disclosed, the rescheduling was the result of the company and its independent registered public accounting firm requiring additional time to review certain disclosures related to the company’s accounting for and disclosures related to the company’s Employee Retention Tax Credit previously received under Section 2301 of the Coronavirus Aid, Relief, and Economic Security Act of 2020,” the company stated in the press release.

To view the webcast, visit https://ibn.fm/ZP4Ek

To view the full press release, visit https://ibn.fm/HeWvF

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Intercept Music, a wholly owned subsidiary of Sanwire (OTC: SNWR), has announced the launch of its latest software version, now incorporating cutting-edge artificial intelligence (“AI”) technology into the music marketing process. As a frontrunner to introduce AI integration, Intercept Music is empowering artists and musicians to level the playing field and market their music on-par with major labels. “We are thrilled to introduce the world’s first AI-integrated music marketing software,” said CEO of Intercept Music, Tod Turner. “At Intercept Music, we believe that every artist deserves the opportunity to succeed in the music industry. With our latest update, we are bridging the gap between independent artists and major labels, providing them with sophisticated tools and resources to effectively promote their music and build a loyal fan base.”

To view the full press release, visit https://ibn.fm/gSQFl

About Sanwire Corporation

Sanwire, a diversified company with a focus on technologies for the entertainment industry, has been involved in aggregating technologies for several years. Sanwire looks for opportunities in fragmented markets, where technology can be applied to consolidate services into a single platform of delivery. The company is focused on advanced entertainment technologies. For more information about the company, visit www.SanwireCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to SNWR are available in the company’s newsroom at https://ibn.fm/SNWR

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, will be participating at this month’s Sidoti & Company Virtual Microcap Conference. The conference is slated for Aug. 17, 2023. During the event, Splash Beverage CEO Robert Nistico will be presenting; his presentation is scheduled to begin at 9:15 a.m. ET. In addition to presenting at the premier event, Nistico will be available for virtual one-on-one meetings with those attending the conference, including potential investors.

To view the presentation, visit https://ibn.fm/2ElSl

To view the full press release, visit https://ibn.fm/YonzM

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and nonalcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• RJD Green announced in May 2023 that its Silex Holdings division had been awarded a major commercial contract worth over $850,000
• For the three months ended May 31, 2023, the company reported revenue of $1.42 million and $290,071 in net operating income
• RJD Green revenue projections for the fiscal year ending August 31, 2023, are $5.1 million, with an expected net profit of $727,250
• The company has monthly recurring revenues of $415,254

RJD Green (OTC: RJDG) is a holding company focused on managing portfolio assets while actively exploring potential acquisitions and opportunities in diversified industries. The company currently operates in three divisions: RJD Green Healthcare Division, Earthlinc Environmental Solutions and Silex Holdings Inc.

The company’s corporate management team has a history of success in both public and private arenas, with diverse enterprise experience that includes RJD Green’s three current market sectors of focus. Corporate overhead is maintained at minimal operating cost, with each officer and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

FE Battery Metals (CSE: FE) (OTCQB: FEMFF) (WKN: A2JC89) today announced assay results from newly discovered lithium pegmatite zones to the southeast of its main Augustus exploratory drilling area at the Augustus Lithium Property in Quebec, Canada. According to the update, the assays are from a recently concluded field prospecting, sampling and mapping program completed with a focus on following up drone and airborne geophysical survey targets identified along an approximately 10 km long structural corridor showing four lithium prospects. Among the highlights, the company reported 11 samples over 1% Li2O and two samples over 2% Li2O with a maximum of 2.58% Li2O from a total of 26 samples collected from Augustus East pegmatites near the NAL mine. In addition, three samples are over 0.50% Li2O. “The company is thrilled about these remarkable assay results from our recent exploration efforts in the lithium-rich region of Quebec, Canada,” said FE CEO Gurminder Sangha. “Importantly, this newly discovered lithium-rich area is located a mere 2.9 kilometers from the mineralized pegmatite bodies of Quebec’s largest lithium mine, the North American Lithium (‘NAL’) mine. The company is carrying out an extensive prospecting, mapping and sampling program during this summer. We look forward to providing further updates on our progress as we proceed with our exploration efforts in this highly prospective region.”

To view the full press release, visit https://ibn.fm/34AYI

About FE Battery Metals Corp.

FE Battery Metals is focused on identifying, exploring and advancing early-stage lithium pegmatite projects in Canada. The company’s primary efforts have been on exploration projects located in Quebec, with its flagship property being the Augustus Lithium Property. Augustus is located in the immediate vicinity of Val d’Or Quebec where several historical prospects and a previously active lithium mine is located within a 10km radius from the property. North American Lithium mine (“NAL”) and the Authier Project are two notable projects in the area that highlight the potential of the Augustus Lithium Property.

NOTE TO INVESTORS: The latest news and updates relating to FEMFF are available in the company’s newsroom at https://ibn.fm/FEMFF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, has inked a new agreement with PlanSource, a leading provider of cloud-based benefits administration and engagement technology. The agreement, which expands Dario’s reach in the employer market, calls for the company to offer integrated digital health solutions to more than 5 million consumers. Dario’s proprietary solutions will support employers and their employees address issues such as diabetes, prediabetes, hypertension, and musculoskeletal and behavioral health. Through its unique services, Dario provides highly personalized solutions, which are driven by billions of data insights and are designed to optimize digital and human support. The new agreement enables employers to select and implement Dario’s integrated chronic-condition management solutions with employee health benefit plans to offer a curated set of benefit solutions in the PlanSource Partner Marketplace. “PlanSource and Dario share the same belief that we need to make it easier for employers to adopt new health benefits, especially as they face tremendous pressures in today’s economy,” said DarioHealth president Rick Anderson in the press release. “We are excited to become a part of the PlanSource Marketplace as a way to improve access to Dario’s solutions for employers and employees alike and make better health outcomes possible for everyone.”

To view the full press release, visit https://ibn.fm/56Ulp

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,724,985 to a deuterated psilocybin analog in Cybin’s CYB003 investigational drug program. “We are very pleased to announce this composition of matter patent supporting our clinical-stage CYB003 program, which strengthens our growing intellectual property portfolio and leadership position as a developer of differentiated therapeutics for mental health, especially as we work diligently to advance our clinical trials towards topline data readouts later this year,” said Doug Drysdale, chief executive officer of Cybin. “With this patent granted, we move forward with conviction in our mission of bringing novel, improved treatment options to people suffering from anxiety and depression.”

To view the full press release, visit https://ibn.fm/KqyCO

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Amesite (NASDAQ: AMST), a leading artificial intelligence (“AI”) software company offering a cloud-based learning platform for education, business and government markets, has renewed its partnership with Central Michigan University (“CMU”). According to the announcement, the U.S. continuing ed sector is projected to grow from $60.52 billion in 2022 to $93.25 billion by 2028, with a compound annual growth rate (CAGR) of approximately 7.47%. The announcement noted that there are 474 regional public universities in the United States, and that each one could benefit from launching professional upskilling programs. “Partnership renewals validate our business model,” said Amesite CEO Dr. Ann Marie Sastry in the press release. “Leveraging our state-of-the-art version 6.3 platform with the latest GPT-4 technology and our comprehensive integration capabilities, we are able to launch solutions quickly and efficiently that generate sustainable university revenue in professional learning and drive growth for Amesite.”

To view the full press release, visit https://ibn.fm/Sc7gX

About Amesite Inc.

Amesite delivers its scalable, customizable, white-labeled online learning platform to universities, businesses, museums and government agencies, enabling them to deliver outstanding digital learning. Amesite provides a single system that combines eCommerce, instruction, engagement, analytics and administration using best-in-class infrastructure to serve multibillion-dollar online learning markets. For more information about the company, please visit www.Amesite.io.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://ibn.fm/AMST

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has rescheduled its conference call to discuss financial results for the second quarter ended June 30, 2023. The company had initially scheduled the call for Aug. 14, 2023, ET. According to the announcement, specific details regarding the call will be forthcoming. “Vivos expects it will be unable to file its Form 10-Q for the quarter ended June 30, 2023, within the prescribed time period,” the company stated in the press release. “The company and its independent registered public accounting firm require additional time to review certain disclosures related to the company’s accounting for and disclosures related to the company’s Employee Retention Credit previously received under section 2301 of the Coronavirus Aid, Relief, and Economic Security Act of 2020. The company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.”

To view the full press release, visit https://ibn.fm/uO4DJ

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective (within the scope of FDA-cleared uses) in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivoS.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Siyata Mobile (NASDAQ: SYTA, SYTAW) (TSX.V: SIM), a global vendor of Push-to-Talk (“PTT”) over Cellular (“PoC”) and cellular signal booster solutions, is reporting on its financial results for the three-month period ended June 30, 2023. Highlights of the report include $2.7 million in revenues, a 180% increase from the $970,000 reported for the same period in 2022; gross profit of $804,000, or 29.7% of revenues, compared to $109,000, or 11.2% of revenues, for the three months ended June 30, 2022; net loss came in at ($2.3) million compared to ($4.3) million in the Q2 2022; and Adjusted EBITDA totaled ($2.0) million compared to ($3.4) million in the same period in the prior year. The report also noted that Siyata had $2 million in cash and working capital of $3.7 million at the end of Q2 2023, compared to $1.9 million and $1.6 million, respectively, as of Dec. 31, 2022. In addition, the company reported that in June 2023, it issued 50 million common shares at a purchase price of $0.045 per share in a public offering, resulting in gross proceeds of $2.25 million.

After June 30, 2023, the company effected a 1-for-100 reverse stock split and issued an additional 51.45 million common shares at a purchase price of $0.045 per share in a registered direct offering for gross proceeds of $2.3 million. “Growth continued to accelerate in the second quarter with a 180% year-over-year increase in revenue on strengthening sales of our mission-critical PoC (MCPTT) SD7 solution,” said Siyata Mobile founder and CEO Marc Seelenfreund in the press release. “Adoption of our critical communications devices is expanding. We have received purchase orders for SD7 handset and its accessories of more than $5 million since the start of 2023, and our resellers also anticipate an increase in demand. Just as important, the increase in orders reaches beyond emergency services to include education, healthcare, industrial and enterprise use cases among others. Given our performance in the first half of the year and our expanding sales pipeline, we are increasingly optimistic that 2023 will be a strong growth sales year for Siyata.”

To view the full press release, visit https://ibn.fm/IRsG3

About Siyata Mobile Inc.

Siyata Mobile is a B2B global vendor of next-generation, Push-to-Talk over cellular devices and cellular booster systems. Its portfolio of in-vehicle and rugged devices enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives. The company’s portfolio of enterprise-grade and consumer cellular-booster systems enables first responders and enterprise workers to amplify cellular signal in remote areas, inside structural buildings where signals are weak and within vehicles for the maximum cellular signal strength possible. For more information about the company, visit www.SiyataMobile.com or www.UnidenCellular.com.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at http://ibn.fm/SYTA

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, is reporting its financial results for the second quarter period ended June 30, 2023. Highlights of the report include a 15% increase in quarterly revenue and a 31% increase in six-month revenues as well as a 32% increase in quarterly gross profit and a 34% increase in six-month gross profit. Specifically, net revenues for Q2 period totaled $5.2 million compared to $4.5 million in the prior year period with six-month revenues totaling $11 million compared to $8.4 million in the prior year period. Gross profit for Q2 period reached $1.7 million compared to $1.3 million in the prior year period, with six-month gross profit reported at $3.5 million compared to $2.6 million in the same period 2022 year. In addition, the report noted that SBEV’s TapouT Energy Drink launched during the second quarter. As of June 30, 2023, the company had total cash and cash equivalents of $903,235, compared with $4.4 million on Dec. 31, 2022. “Our 2023 second quarter results reflect the strengths that we are developing as we grow the business as well as some of the challenges that inevitably emerge in growth businesses,” said Splash Beverage chair and CEO Robert Nistico in the press release.

“Our Qplash platform, which has increased 43% in the first half of the year compared to last year, is developing very nicely on both a business-to-business (‘B2B’) and business-to-consumer (‘B2C’) basis and is now expanding to select international markets. We look for continued contributions from that business. Our quarterly beverage revenues were down slightly in the second quarter, but we attribute that to buying patterns of distributors which can have an impact of timing of sales. The first half beverage sales increased modestly at 7% overall, so we expect a greater upward trend the second half of the year. The beverage business generally ‘stair steps’ it’s way to growth . . . you focus on distribution, support those new placements with marketing and the cycle starts over again. In total, we are where we believe we are supposed to be. Subsequent to the second quarter reporting period, we disclosed an additional $2.7 million raise from existing investors and a $10 million credit facility, which will not only provide us with needed growth capital but also allows us to withdraw the much larger $200 million shelf offering, which has been the source of some investor concern. We remain committed to executing a business plan that relies on four key pillars for success. We have a strong management team, we have a diverse portfolio of brands that match consumer trends, our marketing strategy continues to yield new distribution agreements and retail authorizations, and we have the financial flexibility we need. We look forward to the second half of 2023.”

To view the full press release, visit https://ibn.fm/zcAfY

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and nonalcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Sigma Additive Solutions (NASDAQ: SASI), a leading provider of quality assurance software to the commercial 3D printing industry, is reporting its financial results for the second quarter ended June 30, 2023. Highlights of the report include Q2 revenues of $97,043 compared to revenues of $236,660 for the same period in 2022; gross profit for the quarter of $60,552 compared to $43,585 for Q2 2022; gross margin for Q2 2023 was 62% compared to gross margin of 18% for the prior year quarter; total operating expenses for second quarter 2023 totaled $1.4 million, compared to $2.3 million in 2022; and net loss for the quarter of was reported at $1.3 million, or $0.12 per share. The company had $0.4 million in cash as of June 30, 2023, with cash used in operating activities for the six months ended June 30, 2023, totaling $2.4 million.

“During the second quarter, we continued our progress reducing expenses and cash burn while working with Lake Street Capital Markets and advisors on the exploration of a variety of strategic alternatives,” said Sigma Additive Solutions president and CEO Jacob Brunsberg in the press release. “We expect our expenses to continue to decrease into the third quarter. In our current report on Form 8-K filed with the SEC on July 20, 2023, we reported that we had received four written, nonbinding proposals to purchase assets or acquire the company in a merger or reverse merger and were in talks regarding the respective proposals, as well as possible alternative transactions with other parties that expressed interest in a possible transaction as we worked to formally close our strategic transaction process. We also reported that we had reduced our headcount to a core team we felt important to a possible sale of the company or all or a portion of its assets and support of current customers and had discontinued our product-development activities and ceased to pursue new customers. Since July 20, 2023, we have received additional written, nonbinding proposals as well as revised previous proposals to purchase certain assets of the company and/or acquire the company in a merger or reverse merger. Although we have not yet entered into any definitive agreements, we are continuing to work towards such definitive agreements with interested parties. We look forward to providing additional updates in the weeks to come.”

To view the full press release, visit https://ibn.fm/ByGpO

About Sigma Additive Solutions

Sigma Additive Solutions is a leading provider of in-process quality assurance (“IPQA”) solutions to the additive manufacturing industry. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D(R) for 3D metal and polymer advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies in real time during the manufacturing process, enabling significant cost savings and production efficiencies by reducing waste, increasing yield and shortening cycle times. Sigma believes its software solutions will be a major catalyst for the acceleration and adoption of industrial 3D printing. For more information about the company, please visit www.SigmaAdditive.com.

NOTE TO INVESTORS: The latest news and updates relating to SASI are available in the company’s newsroom at http://ibn.fm/SASI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

RYVYL (NASDAQ: RVYL), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transactions, is reporting on its financial and operational results for the second quarter 2023. Highlights of the report include record quarterly revenue of $14.8 million compared to $6.9 million during the same time period in 2022, a 113% increase, and an 85% increase in Q2 processing volume, which totaled approximately $678 million when excluding the sky financial portfolio volume. In addition, the report showed RYVYL’s FX and international payments portfolio processed $425 million in the second quarter compared to $344 million in business volume in Q1 and $121 million in Q2 2022. During the quarter, the company also announced a partnership with Visa to enable Visa Direct to RYVYL’s customers and a partnership with Intercash, a global payment solutions leader, to expand Banking-as-a-Service platform in Europe; in addition, RYVYL EU received approval to launch Single Euro Payments Area (“SEPA”) Instant Payments in Europe. “Business momentum remained strong during the second quarter leading to record quarterly revenue for the third consecutive quarter of $14.8 million, an increase of nearly 113% year over year, exceeding our guidance of $12.5 to $14 million,” said RYVYL CEO Fredi Nisan in the press release.

“This was accomplished on processing volume of $678 million, an increase of 20% from the first quarter 2023 and also above our guidance range of $580 to $610 million. The increased margin profile is a testament to our steadfast focus on improving processing efficiency, workforce and technology. Against the backdrop of regulatory and banking uncertainty in the United States, we see our subsidiary in Europe, RYVYL EU, as a crucial growth driver for us. . . . We view Banking-as-a-Service as the future of global banking and are excited to be an enabling service provider in a space that is rapidly emerging and reaching new customers every day. By the end of the year, we expect to have a full global payments platform covering over one hundred local currencies and local settlements. . . . Looking ahead, given the strength of our Q2 revenue and continuing momentum, we are raising our Q3 revenue outlook to $16 to $18 million. For 2023, we now expect revenue to exceed $60 million on processing volume of $3 to $4 billion. In terms of profitability, we are lowering our Adjusted EBITDA outlook for 2023 to positive $2 to $3 million. With strong growth in our core processing business, improved margin profile, traction with our Banking-as-a-Service offering and steady progress towards our coyni spinoff initiative, we are in the best position we have ever been to generate long-term sustainable value for our shareholders.”

To view the full press release, visit https://ibn.fm/ABjDI  

About RYVYL

RYVYL was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business and peer-to-peer payment transactions around the globe. By leveraging unique blockchain security and USD-pegged stablecoin technology with near real-time attestation, RYVYL is reinventing the future of financial transactions using its coyni(R) stablecoin platform as a transactional foundation. Since its founding as GreenBox POS in 2017, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity-theft protection and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants and consumers around the globe. For more information about the company, please visit www.RYVYL.com.

NOTE TO INVESTORS: The latest news and updates relating to RVYL are available in the company’s newsroom at https://ibn.fm/RVYL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, is reporting its financial and business results for the quarter ended June 30, 2023. Corporate highlights of the report include initial patient data from UK National Health Service (“NHS”) Miboko Study that indicates weight loss in 100% of participants; sustained development of its proprietary consumer metabolic health platform along with possible deployment as a bolt-on service into existing metabolic and wellness programs; ongoing collaboration with Benchmark Electronics Inc. as a contract manufacturing partner (“CMO”) in developing the manufacture of its proprietary electronic transmitter in anticipation of commercial-sales ramp-up; continued support of its United Kingdom licensee with its application for reimbursement of sensors in the UK; and consistent funding along with the closing of a $6.5 million nondilutive funding in the form of clean debt without any warrants or convertible elements. Financial highlights include R&D expenses totaling $549,012 for the three months ended June 30, 2023; general and administrative expenses reported at $1,508,467 for period ended June 30, 2023; and cash and cash equivalents totaling approximately $4 million for the same period.

To view the full press release, visit https://ibn.fm/M69oX

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a premarket approval application (“PMA”) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence with a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of the company’s BEAT(R) diabetes program that is currently undergoing pilot studies. Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a noninvasive glucose sensor along with an AI mobile application that helps users understand how certain foods and lifestyle habits can impact their overall metabolic health and well-being. Nemaura believes that up to one-half of the population could benefit from a sensor and program that monitors metabolic health and well-being. Nemaura sits at the intersection of the global type 2 diabetes market, which is expected to reach nearly $59 billion by 2025; the $50-plus billion prediabetic market; and the wearable health-tech sector for weight loss and wellness applications, which is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced public offering. The offering was comprised of 4,615,385 shares of the company’s common stock (or common stock equivalents in lieu thereof) as well as warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. According to the announcement, the warrants were immediately exercisable, also at $0.65 per share; the warrants will expire on Oct. 10, 2028. The company announced that gross proceeds from the offering totaled an estimated $3 million, before deducting fees and other offering expenses. 180 Life Sciences anticipates using the funds from the public offering for R&D as well as legal expenses and general corporate purposes, including the preparation of a marketing authorization application for Dupuytren’s Contracture in the United Kingdom and possibly the United States. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.

To view the full press release, visit https://ibn.fm/P1st6

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research and, where appropriate, combination therapy. The company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial results for the three months ended June 30, 2023, and provided an update on its business review. “During the past several months, we have focused on expense reduction to extend runway, optimize marketing mix, and support business development efforts. While this streamlining had a modest unfavorable impact on sales during the quarter, we have gained greater conviction that driving consumer awareness is the next lever that may unlock meaningful growth for UPNEEQ. Importantly, we have also compiled encouraging data around our large total addressable market, or TAM, and the exceptionally low level of consumer awareness for UPNEEQ,” said RVL’s Chief Executive Officer Brian Markison. “In addition, we have continued our strategic business review, and are in advanced discussions with certain companies that we could potentially partner with or acquire to support growth and integrate into our infrastructure with meaningful synergies.”

To view the full press release, visit https://ibn.fm/jtfYr

About RVL Pharmaceuticals plc

RVL Pharmaceuticals is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis. For more information about the company, visit www.RVLPharma.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

LQR House (NASDAQ: LQR), a company that intends to become the full-service digital marketing and brand-development face of the alcoholic beverage space, has closed on its initial public offering. The offering was comprised of 1 million shares of common stock, offered at $5 per share. According to the announcement, the underwriters exercised their overallotment option in full, resulting in an additional 150,000 shares of common stock at the time of the closing. Gross proceeds from the public offering, including overallotments, totaled approximately $5.75 million, before the deduction of any underwriting discounts or offering expenses. EF Hutton, a division of Benchmark Investments, acted as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/kwGkJ

About LQR House Inc.

LQR House is a dynamic and forward-thinking e-commerce marketing company that intends to become the full-service digital marketing and brand-development face of the alcoholic beverage space. Currently, LQR House has a key partnership with Country Wine & Spirits Inc., granting the company full control over all marketing operations on CWSpirits.com, a large alcohol ecommerce platform. With a deep passion for the world of beverages, LQR House takes pride in curating marketing strategies aimed to elevate brands to new heights. Composed of a team of seasoned professionals, LQR House focuses on crafting marketing solutions tailored to each client’s unique needs. Through strategic partnerships, creative branding and digital prowess, LQR House intends to be at the forefront of the wine and spirits marketing landscape, making it the go-to choice for brands seeking to thrive in a competitive industry. For more information about the company, please visit www.LQRHouse.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, has filed for an extension to file its quarterly report. The company filed the extension on Form 10-Q for the second quarter pursuant to a Form 12b-25 filed with the U.S. Securities and Exchange Commission (“SEC”). According to the announcement, TRxADE is “not able to timely file its 10-Q by August 14, 2023, the original due date for such filing, without unreasonable effort or expense, because additional time is required to finalize its financial statements and related disclosures required to be included in the 10-Q in connection with the recent merger transaction it completed in July.” The company noted that it will release Q2 2023 financial results on Aug. 18, 2023, after the market closes.

To view the full press release, visit https://ibn.fm/QoVLg

About TRxADE Health Inc.

TRxADE is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug-procurement marketplace serving more than 14,500 members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient centric telehealth services. For more information about the company, please visit www.TRxADE.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Splash Beverage Group (NYSE American: SBEV), a portfolio company of leading beverage brands, today announced it has established a $10 million operating capital credit facility with a European and Singapore-based private funding group. According to the update, the company will use the credit facility along with additional funds raised for operating capital and will withdraw its existing $200 million S-3 Registration Statement. “We are very pleased to enter into this agreement and onboard capital from our existing investors. This $12.7 million in total ensures the company is well funded and will be used to fuel growth as we focus on reaching profitability,” said Splash’s CEO Robert Nistico. “The flexibility and availability of this capital allows us to retire our existing public shelf offering, which underscores our commitment to prudent capital allocation and responsible financial management. We remain committed to delivering value to our shareholders and are focused on executing our strategic plans to drive sustainable long-term growth.”

To view the full press release, visit https://ibn.fm/10Occ

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, today announced the signing of an agreement for two proof-of-concept (“POC”) projects with a leading global vehicle manufacturer. The POC projects aim to assess the accuracy of Foresight’s unique automatic calibration capabilities in enhancing 3D depth perception. In addition, the vehicle manufacturer will assess Foresight’s Mono2Stereo(TM) perception enhancement solution to be used with its existing mono cameras, which have different fields of view. “We believe that our collaboration with another leading global vehicle manufacturer validates the importance of Foresight’s technology in the automotive world and could lead to additional opportunities in the automotive sector,” said Haim Siboni, CEO of Foresight. “This vote of confidence from an important player in the automotive industry reinforces our commitment to develop advanced software-based vision solutions that will be widely implemented and could save lives by redefining road safety.”

To view the full press release, visit https://ibn.fm/HW0DN

About Foresight Autonomous Holdings Ltd.

Foresight is a technology company developing smart multi-spectral vision software solutions and cellular-based applications. Through the company’s wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions. Foresight’s vision solutions include modules of automatic calibration and dense three-dimensional (“3D”) point cloud that can be applied to different markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobile’s cellular-based solution suite provides real-time pre-collision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics. For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.ForesightAuto.com.

NOTE TO INVESTORS: The latest news and updates relating to FRSX are available in the company’s newsroom at http://ibn.fm/FRSX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting unaudited financial results for its first quarter, the period ended June 30, 2023, as well as recent business highlights. Financial numbers show cash total of C$9.3 million as of June 30, 2023, with the total increasing to C$18 million as of Aug. 14, 2023. Net loss for the quarter totaled C$14.5 million for the quarter with operating expenses reaching C$12.7 million for the quarter. Business highlights include the initiation of dosing in cohort 6, the final cohort of the company’s phase 2 study of CYB003 in Major Depressive Disorder (“MDD”), following the successful completion of cohort 5; a partnership with Worldwide Clinical Trials to support the future clinical development and regulatory strategy for CYB003 in MDD; the development of EMBARK(CT), a scalable psychedelic facilitation training program, designed to support larger pivotal studies; and continued advancement of the phase 1 CYB004-E study, with CYB004 dosing underway in part C, the final portion of the study. In addition, the company announces results of the Flow Kernel feasibility study, which Cybin sponsored; the results were published in the “Scientific Reports” journal.

The company also closed an $8.25 million marketed public offering to support the clinical development of CYBN’s CYB003 and CYB004 programs. “The steady clinical progress we have made over the past few months is truly encouraging, with dosing initiated in the final cohort of our phase 2 CYB003 MDD study and CYB004 dosing underway in part C of our phase 1 CYB004-E study,” said Cybin CEO Doug Drysdale in the press release. “We expect topline data for our CYB003 and CYB004 programs later this year, which we anticipate will provide insights into the therapeutic profile of our deuterated molecules as potentially differentiated treatments for mental health conditions. The recent marketed public offering further strengthens our position to deliver on these value-driving milestones. I am proud of the Cybin team’s thoughtful approach and strategic decisions that have enabled us to accelerate our clinical-stage programs. We look to build on this momentum as we advance to future pivotal studies, with work already underway in developing a scalable version of our EMBARK psychedelic facilitation program and through our partnership with Worldwide Clinical Trials, a global contract research organization.”

To view the full press release, visit https://ibn.fm/88k4b

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Lottery.com (NASDAQ: LTRY), a leading provider of lottery results data servicing global publishers, search engines and voice assistants, has appointed Christopher Anderson Gooding to its board of directors, a move the company is calling “another important step in a new era of compliance with NASDAQ.” Gooding brings an impressive resume to his new responsibility. He has served for decades at respected law firms, primarily those in  the heart of London’s financial district. His roles have included partner, consultant, director, and legal strategist. Gooding has rich experience, particularly in the corporate landscape, where he has been a founding director of a substantial N.Y.-based hedge fund valued at more than $500 million, served on the boards of companies in aviation and insurance, and led initiatives in the green-energy and aviation sectors.

According to the announcement, Lottery.com is focusing on resuming operations in three major segments of its business model — B2C ticket sales, international expansion and technology licensing — before the end of the year. “We extend a very warm welcome to Christopher,” said Lottery.com board chairman and interim CEO Matthew McGahan in the press release. “The appointment of an individual of his stature enriches our board substantially. His legal acumen, coupled with a deep understanding of corporate governance, greatly augments our combined senior leadership experience. Bolstered by these strategic appointments and solid UCIL financing, we now have a much more robust operational and financial foundation to execute on our business plan. As we lean in to the second half of our fiscal year, our strategy’s central interest is to restore the company’s revenue-driving operations. Our business is easily scalable, contains inherent potential and we look forward to updating the market on these and other positive developments in due course.”

To view the full press release, visit https://ibn.fm/jS28A

About Lottery.com Inc.

Lottery.com, Inc. is a leading technology company that is transforming how, where and when lotteries are played. Its engaging mobile and online platforms enable players and commercial partners located throughout the United States and other countries to remotely purchase safe and legally sanctioned lottery games. Lottery participants look to the Company’s website, Lottery.com, for compelling, real-time results on more than 800 lottery games from more than 40 countries. Lottery.com’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. To learn more about the company, visit www.Lottery.com.

NOTE TO INVESTORS: The latest news and updates relating to Lottery are available in the company’s newsroom at https://ibn.fm/Lottery

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Golden Matrix (NASDAQ: GMGI), a developer, licensor and global operator of online gaming and eCommerce platforms, systems and gaming content, announced that the company is reporting record third-quarter revenues for the period ending July 31, 2023. According to the announcement, revenues for the period exceeded $11 million, with significant contributions coming from RKings Tournament Competitions, the company’s B2C segment operating in the United Kingdom. The company noted that operational improvements at RKings accounted for the revenue growth, including the introduction and popularity of an expanded tournament platform offering multiple prizes of various types and prices. The company noted that another factor in the uptick in revenue is the continued growth of GMGAssets, a complementary business that offers those who win an expensive car or other high-ticket item in RKings tournaments the option to choose a predetermined cash prize instead.

According to the report, RKings revenue from tournament competitions and GMGAssets in Q3 totaled $5.8 million and $1.7 million, respectively. The company also noted that its fully regulated online casino and sportsbook MEXPLAY continues to show consistent progress since its launch earlier this year. “July marked our best monthly financial results at RKings since it was acquired almost two years ago,” said Golden Matrix CEO Brian Goodman in the press release. “It contributed $7.5 million toward total revenues in the quarter, which is $1 million more than contributions of about $6.5 million generated in both Q1 and Q2. . . . In addition to generating record revenues exceeding $11 million for the first time, we made excellent progress during the quarter in securing the financing required to complete the acquisition of the MeridianBet Group; and we anticipate sending out the proxy statement later this month for shareholder approval. Obviously, we are extremely excited to complete this transaction, as it will transform GMGI into a dynamic and highly profitable global gaming company.”

To view the full press release, visit https://ibn.fm/f4Jie

About Golden Matrix Group Inc.

Golden Matrix Group, based in Las Vegas, Nevada, is an established B2B and B2C gaming technology company operating across multiple international markets. The B2B division of Golden Matrix develops and licenses proprietary gaming platforms for its extensive list of clients. RKings, GMGI’s B2C division, operates a high-volume ecommerce site enabling end users to enter paid-for competitions on its proprietary platform in authorized markets. The company also owns and operates MEXPLAY, a regulated online casino in Mexico. The company’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with current U.S. law. For more information about the company, visit www.GoldenMatrix.com.

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, has secured an additional $6.5 million in nondilutive funding. The company announced the funding was secured through a clean debt facility with no warrants or convertible elements from an existing lender. In addition, the company noted that it recently participated in the American Diabetes Association meeting, the world’s largest gathering of diabetes professionals. The company demonstrated product at the event, receiving “very encouraging feedback” from attendees including corporate officials, diabetes service providers and clinicians. “The company is also currently undertaking studies with the National Health Service (‘NHS’) in the UK with its metabolic health program designed for the consumer market targeting obesity and prediabetes whilst refining its commercial offering in this space,” the announcement stated. “Nemaura also continues to support its UK licensee with its application for reimbursement of sugarBEAT(R) in the UK.”

To view the full press release, visit https://ibn.fm/mfWpo

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a premarket approval application (“PMA”) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence (“AI”) under a digital healthcare subscription service as part of NMRD’s BEAT diabetes program. Nemaura sits at the intersection of the global type 2 diabetes market, which is expected to reach nearly $59 billion by 2025; the $50-plus billion prediabetic market; and the wearable health-tech sector for weight loss and wellness applications, which is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Astra Energy (OTCQB: ASRE), a renewable and waste-to-energy project developer and technology acquisition company, announced that it has paid off the only convertible note on the company’s balance sheet. According to the announcement, Ron Loudoun, the company’s new chair and CEO, prepaid the note to avoid any potential dilution to the company’s stock and to protect shareholder interest. Loudoun brings an impressive resume to his new position, with  experience in business development and operational leadership as well as a proven track record of achieving common goals that advance aligned strategic priorities for the companies he is serving. “Astra is at a very exciting operational inflection point,” said Astra Energy CEO and chair Ron Loudoun in the press release. “Years of concerted effort and business development have brought the company to a point where both the Holcomb and Regreen technologies can be presented to a backlog of potential customers. With manufacturing in place, the timing for this company to advance could not be better. We are looking forward to a very rewarding time for all stakeholders.”

To view the full press release, visit https://ibn.fm/g0iU9

About Astra Energy Inc.

Astra Energy is an integrated solutions provider investing in and developing clean and renewable energy projects in markets where demand is high, supply is limited and there is an opportunity to address other imminent market needs. Astra’s corporate strategy is rooted in securing technologies and assets; identifying viable market opportunities; and bringing together resources, expertise, technology and defined action plans to execute first-in-class projects that benefit communities, local economies, the planet and the company’s investors. The company’s goal is to create a more secure and sustainable power sector that supports its purpose, mission and values to transform the economic, environmental and social landscape for generations to come. For further information about the company, visit www.AstraEnergyInc.com

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Breezer Ventures (OTC: BRZV) and its wholly owned subsidiary, Magnum Finest Spirits Inc., are key players in the $1.6 trillion global alcohol drinks industry, and the companies are discussing Magnum’s potential for growth and development in the space. According to the announcement, Breezer and Magnum’s goal is to capture a significant piece of the market using centuries-old distilling techniques” along with effective marketing to create a long-term relationship between consumers and the Magnum 1770 brand. The company noted that liquor companies that have focused on this objective have often been ”rewarded handsomely by buyouts from global alcohol distribution conglomerates like Diageo.” In addition, the company noted celebrity endorsements and deals that similar companies have announced, which illustrate that the value in a successful liquor company can be measured internationally.

The discussion noted, however, that many of these companies are private corporations, which means there is no opportunity for the general population to invest or profit from this potential. “In spirits, the expected growth rate through 2026 is a strong 5.9%,” the company reported in the press release. “In the alcohol drinks industry, population growth is the main driver of the market. Global population growth is expected to reach 10 billion by 2050. . . . The industry has been stuck on glass and plastic for decades, neither are effectively recycled, contrary to popular opinion. Magnum’s goal using BiB packaging is to pioneer change in the consumer’s perception of boxed alcohol. . . . The box is a statement. It delivers that high-quality product in ecofriendly packaging, with cardboard being easily recyclable, biodegradable and even compostable. It is cheaper to produce and has a lower carbon footprint than glass. It is also lighter, safer and more cost effective to everyone along the way, easier and cheaper to transport or ship, from the distiller to the distributor/wholesaler, to the retailer and consumer. Breezer and Magnum management consider themselves very fortunate to have world-class spirits made by their partners with 300 years’ experience.”

To view the full press release, visit https://ibn.fm/rD7WL

About Breezer Ventures Inc./Magnum Finest Spirits Inc.

Magnum is a distilled spirits and marketing company offering products with a centuries-long history of outstanding quality. What separates Magnum from industry peers is its functionally innovative and environmentally conscious Bag in a Box (“BiB”) packaging and distinctive billboard-style labeling. Never to be associated with discount or bulk, top-shelf Magnum 1770-branded products include an exceptional Bourbon, premium Vodka and an esteemed Gin, as well as trending Flavored Spirits. The company plans to expand on its relationships with the big box wine and liquor stores, warehouse liquor emporiums, traditional liquor stores, VIP and trending restaurants, bars and nightclubs. For more information about this company, please visit www.MagnumFinestSpirits.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, has signed a paid proof of concept (“POC”) project with the Chinese subsidiary of one of the world’s leading manufacturers of industrial equipment, heavy machinery, construction and mining equipment. According to the announcement, the Fortune 500 company is evaluating the ability of Foresight’s QuadSight(R) technology to provide autonomous capabilities to the company’s mining and construction trucks; a successful outcome may mean that FRSX’s proprietary tech could be integrated into future vehicles. The company noted that it was chosen over other three-dimensional perception vision solutions because of its accurate and high-resolution point cloud and all-object detection capabilities in diverse circumstances, including harsh weather, environment and lighting conditions. “We are excited to extend our innovative stereo vision solutions to the construction and mining industry,” said Foresight CEO Haim Siboni in the press release. “By collaborating with one of the world’s largest industrial equipment and heavy machinery manufacturers, we aim to enhance the safety, accuracy of object detection, and environmental awareness in their operations. This POC project reflects our dedication to delivering advanced automotive vision technologies across diverse sectors.”

To view the full press release, visit https://ibn.fm/DTdb3

About Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings is a technology company developing smart multispectral vision software solutions and cellular-based applications. Through the company’s wholly owned subsidiaries — Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd. — Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions. Foresight’s vision solutions include modules of automatic calibration and dense three-dimensional (“3D”) point cloud that can be applied to different markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobile’s cellular-based solution suite provides real-time, precollision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics. For more information, visit the company’s website at www.ForesightAuto.com.

NOTE TO INVESTORS: The latest news and updates relating to FRSX are available in the company’s newsroom at http://ibn.fm/FRSX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Fintech Ecosystem Development Corp. (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), is exploring the use of artificial intelligence (“AI”) to power financial solutions. “As a company that understands the financial sector, FEXD knows the potential that artificial intelligence (‘AI’) has and the value it brings in transforming an industry that has, for a long time, arguably lacked innovation,” a recent article reads. “With a growing range of applications, from simple chatbots to credit risk management tools, AI is finding its way to the core of financial solutions, and all stakeholders welcome it. So far, JPMorgan Chase, critical among other players in its space, has reported leveraging AI for fraud detection for its account holders. As a showcase of what AI is capable of, the bank has been able to implement a proprietary algorithm that detects fraud patterns, earning it high scores in both security and reliability. This, along with other additional benefits, such as speeding up services, allowing financial institutions to make more informed risks, and creating avenues for better customer relationship management, point to the potential of AI in the financial space. By focusing on such, FEXD is pushing the AI conversation forward while exploring ways to develop this technology further to address unmet mobile money needs in developing and industrialized countries and markets.”

To view the full article, visit https://ibn.fm/eKbRm

About Fintech Ecosystem Development Corp.

Fintech Ecosystem Development is a special purpose acquisition company formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector. The company is sponsored by Revofast LLC and the management team led by CEO, president and founder Dr. Saiful Khandaker and a group of experienced fintech business and technology innovators. For more information about the company, please visit www.FintechEcosys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, anticipates releasing its second quarter 2023 financial results on Aug. 14, 2023, after the market closes. In addition, the company announced that it will host a conference call and webinar to discuss the report and provide an overview of the company’s milestones and developments; the call will at 5 p.m. ET, also on Aug. 14. Those interested in listening to the call can dial toll-free at 888-886-7786; international callers may dial 416-764-8658. A replay of the event will be available after the call and can be accessed by dialing 844-512-2921 (412-317-6671 for international callers). All calls will require the following passcode: 22348893.

To view the live webcast, visit https://ibn.fm/2cPET

To view the full press release, visit https://ibn.fm/pbrHf

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective (within the scope of FDA-cleared uses) in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivosLife.com.  

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Exro Technologies (TSX: EXRO) (OTCQB: EXROF), a leading clean-technology company that has developed new-generation power control electronics that expand the capabilities of electric motors and batteries, has released its financial results for the three months and six months ending June 30, 2023. Highlights of the report included revenue of $2,443,292 for the three-month period and $2,768,061 for the six-month period; the signing of a definitive commercialization agreement with Linamar Corporation, a global tier-1 automotive supplier; the closing of a common share bought deal financing for aggregate gross proceeds of of $34,931,250; and the election of three new directors — Aleksandra Miziolek, Anita Ganti and Frank Simpkins ­— along with the appointment of board chair Rod Copes. “The second quarter of 2023 demonstrated continued progress towards commercialization of our next generation technologies for electric vehicles and stationary energy storage,” said Exro Technologies CEO Sue Ozdemir in the press release. “We finished the quarter in a strong financial position, significantly expanded the expertise of our board of directors, and are in final preparations to start our production before the end of Q3. We have customers proceeding towards additional purchase orders and are digging in with our new leading global automaker partner on our power train innovation project — evidence that we are capitalizing on the efforts we have put in over the last three years.”

To view the full press release, visit https://ibn.fm/uNArZ

About Exro Technologies Inc.

Exro is a clean-tech company that has developed a new class of control technology for electric powertrains. Exro’s advanced motor-control technology, its Coil Driver, expands the capabilities of electric motors and powertrains. The Coil Driver enables two separate torque profiles within a given motor. The first is calibrated for low speed and high torque, while the second provides expanded operation at high speed. The ability to change configuration allows efficiency optimization for each operating mode, resulting in overall reductions in energy consumption. The controller automatically and seamlessly selects the appropriate configuration in real-time so that torque demand and efficiency are optimized. The limitations of traditional electric machines and power technology are becoming more evident. In many increasingly prominent applications, traditional methods cannot meet the required performance. This means either oversizing the equipment, adding additional motors or implementing heavy mechanical-geared solutions. Exro offers a new solution for system optimization through implementation of the technology, which can yield the following results: increased drive cycle efficiency, reduced system volume, reduced weight, and expanded torque and speed capabilities. Exro allows the application to achieve more with less energy consumed. For more information about the company, please visit www.Exro.com.

NOTE TO INVESTORS: The latest news and updates relating to EXROF are available in the company’s newsroom at http://ibn.fm/EXROF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork